- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Luspatercept-aamt Reduces RBC Transfusion Burden in Patients With Rare Blood Disorder
June 13th 2020, 6:00pm
European Hematology Association Congress
Data from the BELIEVE trial showed that luspatercept-aamt, a first-in-class erythroid maturation agent designed to regulate late-stage red blood cell maturation, reduced the need for red blood cell transfusions across every subgroup of patients with beta-thalassemia.
Early Data Show CC-93269 has Activity in Multiple Myeloma
June 13th 2020, 6:00pm
European Hematology Association Congress
Interim results from a phase 1 trial show CC-93269 has activity in highly refractory, heavily pretreated patients with multiple myeloma, with an acceptable safety profile.
Dr. Cluzeau on the Efficacy of APR-246/Azacitidine in TP53-Mutated MDS and AML
June 13th 2020, 5:53pm
European Hematology Association Congress
Thomas Cluzeau, MD, PhD, discusses the response rates of a phase 2 study with APR-246 and azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia.
Dr. DiNardo on the Results of the VIALE-A Trial in AML
June 13th 2020, 10:00am
European Hematology Association Congress
Courtney DiNardo, MD, MSCE, discusses the results of the phase 3 VIALE-A trial in acute myeloid leukemia (AML).
Adding Subcutaneous Daratumumab to CyBorD Improves Outcomes for AL Amyloidosis
June 13th 2020, 6:30am
European Hematology Association Congress
Subcutaneous daratumumab may be a promising treatment for newly diagnosed patients with light chain amyloidosis who are in urgent need of new treatment options.
Venetoclax/Azacitidine Showcases OS Benefit in Older Patients With AML
June 13th 2020, 6:30am
European Hematology Association Congress
The combination of venetoclax (Venclexta) and azacitidine led to a 34% reduction in the risk of death versus azacitidine alone in treatment-naïve patients with acute myeloid leukemia who are ineligible for intensive therapy.
Narsoplimab Significantly Improves Outcomes in HSCT-TMA
June 12th 2020, 11:14pm
European Hematology Association Congress
Treatment with narsoplimab (OMS721) led to complete responses, improved laboratory markers, and encouraging 100-day survival rates in patients diagnosed with hematopoietic stem cell transplant-thrombotic microangiopathy.
Liso-Cel Induces High Response Rates in High-Risk Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
June 12th 2020, 10:00pm
European Hematology Association Congress
Treatment with the CAR T-cell product lisocabtagene maraleucel led to high response rates, with durable complete responses, in transplant-ineligible patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma who had poor prognostic features.
Dr. Hari on the Role of MRD in Multiple Myeloma
June 12th 2020, 9:22pm
European Hematology Association Congress
Parameswaran Hari, MD, MRCP, discusses the role of minimal residual disease in multiple myeloma.
Dr. Costa on Safety of CC-93269 in Relapsed/Refractory Myeloma
June 12th 2020, 9:12pm
European Hematology Association Congress
Luciano J. Costa, MD, PhD, discusses the safety results of CC-93269 in patients with relapsed/refractory multiple myeloma.
Serum Biomarkers Are Early Predictors for Haplo-SCT Outcomes
June 12th 2020, 7:05pm
European Hematology Association Congress
Higher levels of the serum biomarkers ST2 and REG3α were associated with increased incidence of graft-vs-host disease and increased risk for transplant-related mortality in patients who have undergone haploidentical stem-cell transplantation with post-transplant cyclophosphamide.
Pegcetacoplan Outperforms Current Standard of Care in Paroxysmal Nocturnal Hemoglobinuria
June 12th 2020, 6:30am
European Hematology Association Congress
The novel C3 inhibitor pegcetacoplan led to a significant improvement in hemoglobin level and other clinical outcomes at week 16 versus the current standard of care, eculizumab in patients with paroxysmal nocturnal hemoglobinuria.
Ruxolitinib Improves Outcomes in aGVHD Across Subgroups
June 12th 2020, 6:30am
European Hematology Association Congress
Ruxolitinib (Jakafi) induced a strong, durable response across several subgroups of patients with steroid-refractory acute graft-versus-host disease.
Ibrutinib/Venetoclax Triplet Demonstrates Frontline Activity in High-Risk CLL
June 12th 2020, 6:30am
European Hematology Association Congress
The triplet regimen of ibrutinib, venetoclax, and obinutuzumab demonstrated encouraging response rates with an acceptable safety profile in treatment-naïve patients with high-risk chronic lymphocytic leukemia.
Imetelstat Provides Promising, Durable Transfusion Independence in Lower-Risk MDS
June 12th 2020, 6:30am
European Hematology Association Congress
Imetelstat demonstrated meaningful and durable transfusion independence in patients with lower-risk myelodysplastic syndrome that are non-del(5q), dependent on red blood cell transfusion, and are relapsed/refractory to treatment with erythropoiesis-stimulating agents.
Omitting Radiation Does Not Reduce Survival for Patients with Early Unfavorable HL
June 12th 2020, 6:30am
European Hematology Association Congress
Radiation therapy can be omitted in patients with newly diagnosed early-stage unfavorable Hodgkin lymphoma without sacrificing efficacy.
Dr. Usmani on Activity of Teclistamab in Relapsed/Refractory Multiple Myeloma
June 1st 2020, 2:04am
Saad Usmani, MD, discusses research with teclistamab (JNJ-64007957) in relapsed/refractory multiple myeloma presented at the 2020 ASCO Virtual Scientific Program.
Alectinib Continues to Maintain Significant OS Benefit in ALK+ NSCLC
June 1st 2020, 12:02am
The highly selective second-generation TKI alectinib demonstrated a clinically meaningful improvement in overall survival compared with crizotinib in patients with ALK-positive non–small cell lung cancer.
Tepotinib Displays Durable Clinical Benefit in METex14-Altered NSCLC
May 31st 2020, 11:07pm
The oral, highly selective MET inhibitor tepotinib demonstrated durable clinical activity in patients with locally advanced or metastatic non–small cell lung cancer who harbor a MET exon 14 skipping mutation identified through liquid or tissue biopsy.
Robust Data and Multivariate Analyses Support Cabazitaxel as a Standard of Care in mCRPC
May 31st 2020, 10:57pm
The use of cabazitaxel over abiraterone acetate or enzalutamide may continue as a standard of care in men with metastatic castration-resistant prostate cancer who were previously treated with docetaxel and either of those 2 androgen receptor-targeted agents.